KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Payables (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 9 years of Payables data on record, last reported at $55.5 million in Q4 2025.

  • For Q4 2025, Payables rose 4720.59% year-over-year to $55.5 million; the TTM value through Dec 2025 reached $55.5 million, up 4720.59%, while the annual FY2025 figure was $55.5 million, 4720.59% up from the prior year.
  • Payables reached $55.5 million in Q4 2025 per AMRX's latest filing, down from $68.2 million in the prior quarter.
  • Across five years, Payables topped out at $596.2 million in Q2 2021 and bottomed at $40000.0 in Q1 2025.
  • Average Payables over 5 years is $236.2 million, with a median of $49.4 million recorded in 2023.
  • The widest YoY moves for Payables: up 4720.59% in 2025, down 99.91% in 2025.
  • A 5-year view of Payables shows it stood at $525.3 million in 2021, then plummeted by 92.36% to $40.1 million in 2022, then increased by 8.11% to $43.4 million in 2023, then tumbled by 97.35% to $1.2 million in 2024, then surged by 4720.59% to $55.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Payables were $55.5 million in Q4 2025, $68.2 million in Q3 2025, and $100000.0 in Q2 2025.